

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> – Percheron Therapeutics Limited
<b>ABN</b> – 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	James Garner
<b>Date of last notice</b>	23 December 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Not applicable
<b>Date of change</b>	15 April 2026
<b>No. of securities held prior to change</b>	<b>Fully paid ordinary shares</b> 53,500,000  <b>Unquoted options</b> 6,690,000 exercisable at 7c per option on or before 7 Aug 2028  3,000,000 exercisable at 8.3c per option on or before 4 July 2029  5,000,000 exercisable at 3.5c per option on or before 20 May 2028.
<b>Class</b>	Fully paid ordinary shares and unquoted options
<b>Number acquired</b>	21,400,000 fully paid ordinary shares and 10,700,000 unquoted options
<b>Number disposed</b>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$107,000
<b>No. of securities held after change</b>	<p><b>Fully paid ordinary shares</b> 74,900,000</p> <p><b>Unquoted options</b> 6,690,000 exercisable at 7c per option on or before 7 Aug 2028</p> <p>3,000,000 exercisable at 8.3c per option on or before 4 July 2029</p> <p>5,000,000 exercisable at 3.5c per option on or before 20 May 2028.</p> <p>10,700,000 exercisable at 1c per option on or before 15 April 2028</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Take up of Entitlement under the Percheron Therapeutics Entitlement Offer announced 16 March 2026.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	Not applicable
<b>Name of registered holder (if issued securities)</b>	Not applicable
<b>Date of change</b>	Not applicable
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
<b>Interest acquired</b>	Not applicable
<b>Interest disposed</b>	Not applicable
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
<b>Interest after change</b>	Not applicable

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	Not applicable – Excluded trading as defined at Section 2.10 of the Percheron Therapeutics Securities Trading Policy.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

<sup>+</sup> See chapter 19 for defined terms.